Aimovig, a medication for migraine prevention, was approved by the U.S. Food and Drug Administration (FDA) in May 2018 [1]. It is manufactured by Amgen [2].
What is Aimovig used for?
Aimovig is a calcitonin gene-related peptide (CGRP) inhibitor used for the preventive treatment of migraine in adults [2]. It is administered via subcutaneous injection [3].
How does Aimovig work?
Aimovig works by blocking the activity of CGRP, a molecule that is thought to play a role in migraine [2]. By preventing CGRP from binding to its receptor, Aimovig helps to reduce the frequency of migraine attacks [3].
How is Aimovig administered?
Aimovig is typically administered as a once-monthly injection [3]. Patients can self-inject the medication at home after receiving training [3].
What are the potential side effects of Aimovig?
Common side effects of Aimovig can include injection site reactions (redness, itching, or swelling), muscle pain, and constipation [2]. Serious side effects are rare but can include allergic reactions [2].
What is the patent situation for Aimovig?
The patent landscape for Aimovig, like other pharmaceuticals, is complex and can be tracked through resources like DrugPatentWatch.com [4]. Pharmaceutical patents grant exclusive marketing rights for a specific period, impacting when generic versions can enter the market [4]. Understanding these patent timelines is crucial for assessing future market competition and drug accessibility [4].